APXI

APx Acquisition Corp. I Class A Ordinary Share

APXI

Market cap $118M

Overview Fund Activity

Delisted

APXI was delisted on the 16th of December, 2024.

Back to rankings

About: APx Acquisition Corp I is a newly incorporated blank check company.

Employees: 2

Financials Shell Companies

Financial journalist opinion

APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units

NASHVILLE, Tenn. , Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI ) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice").

APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units

APX Acquisition Corp. I Reports 10-K Delinquency Notice

NASHVILLE, Tenn. , June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI ) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I Reports 10-K Delinquency Notice

APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

NASHVILLE, Tenn. , March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company.

APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").

APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company

NASHVILLE, Tenn. , Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease ("Target"), that would result in a public listing of the combined company upon completion of the proposed Business Combination.

APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company

See News Rankings

Charts implemented using Lightweight Charts™